b|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

Klebsiella pneumoniae, Strain MRSN 368001

Catalog No. NR-55546

This reagent is the tangible property of the U.S. Government.

Product Description:

Klebsiella pneumoniae (K. pneumoniae), strain MRSN 368001 was isolated in 2015 from a human wound sample in Africa as part of a global surveillance program. NR-55546 was deposited as an extensively drug-resistant strain (XDR), sensitive to tetracycline and tigecycline and resistant to amikacin, ampicillin/sulbactam, aztreonam, cefepime, ceftazidime, ceftriaxone, ceftazidime/avibactam, ceftolozane/tazobactam, ciprofloxacin, ertapenem, meropenem, gentamicin, imipenem, levofloxacin, piperacillin/tazobactam, tobramycin and trimethoprim/sulfamethoxazole. NR-55546 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70050653

Manufacturing Date: 03MAR2022

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: <u>Contact@BEIResources.org</u>. We try to respond to feedback within 24 hours.

| TEST | SPECIFICATIONS | RESULTS |
|---|---|---|
| Phenotypic Analysis | | |
| Cellular morphology | Gram-negative rods | Gram-negative rods |
| Colony morphology | Report results | Circular, convex, entire, smooth, mucoid and cream (Figure 1) |
| Motility (wet mount) | Report results | Non-motile |
| VITEK [®] 2 (GN card) | K. pneumoniae (≥ 89%) | K. pneumoniae (95%) |
| Antibiotic Susceptibility Profile ^{1,2} | | |
| Amikacin | Resistant | Resistant (≥ 64 µg/mL) |
| Ampicillin/sulbactam | Resistant | Resistant (≥ 32 µg/mL) |
| Aztreonam | Resistant | Resistant (≥ 64 µg/mL) |
| Cefepime | Resistant | Resistant (≥ 64 µg/mL) |
| Ceftazidime | Resistant | Resistant (≥ 64 µg/mL) |
| Ceftazidime/avibactam | Resistant | Resistant (≥ 256 µg/mL) |
| Ceftolozane/tazobactam | Resistant | Resistant (≥ 256 µg/mL) |
| Ceftriaxone | Resistant | Resistant (≥ 64 µg/mL) |
| Ciprofloxacin | Resistant | Resistant (≥ 32 µg/mL) |
| Ertapenem | Resistant | Resistant (≥ 8 µg/mL) |
| Gentamicin | Resistant | Resistant (≥ 16 µg/mL) |
| Imipenem | Resistant | Resistant (≥ 32 µg/mL) |
| Levofloxacin | Resistant | Resistant (≥ 8 µg/mL) |
| Meropenem | Resistant | Resistant (≥ 16 µg/mL) |
| Piperacillin/tazobactam | Resistant | Resistant (≥ 128 µg/mL) |
| Tetracycline | Sensitive | Sensitive (≤ 1 μg/mL) |
| Tigecycline | Sensitive | Sensitive (≤ 0.5 µg/mL) ³ |
| Tobramycin | Resistant | Resistant (≥ 16 µg/mL) |
| Trimethoprim/sulfamethoxazole | Resistant | Sensitive (≤ 32 µg/mL) ⁴ |
| Genotypic Analysis | | |
| Sequencing of 16S ribosomal RNA gene (~ 1480 base pairs) | ≥ 99% sequence identity to K. pneumoniae, strain MRSN 368001 (GenBank: JAGYDN010000074.1) | 99.9% sequence identity to <i>K. pneumoniae</i> , strain MRSN 368001 (GenBank: JAGYDN010000074.1) |

E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898

Certificate of Analysis for NR-55546

SUPPORTING INFECTIOUS DISEASE RESEARCH

| TEST | SPECIFICATIONS | RESULTS |
|--|--|--|
| Purity 7 days at 37°C in an aerobic atmosphere with and without 5% CO ₂ on Tryptic Soy agar | Growth consistent with expected colony morphology | Growth consistent with expected colony morphology |
| Viability | Growth | Growth |

¹Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

²Antibiotic susceptibility was tested using a combination of bioMérieux VITEK[®]2 GN74 and ETEST[®].

³MIC Interpretation Guideline: EUCAST Version 8.0 (2018)

⁴K. pneumoniae, strain MRSN 368001 was deposited as resistant to trimethoprim/sulfamethoxazole, but showed a MIC of ≤ 32 µg per mL (interpreted as sensitive) for this antibiotic during QC testing. Testing was performed in duplicate.

/Heather Couch/

Heather Couch

Program Manager or designee, ATCC Federal Solutions

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.

ATCC[®] is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.



13 MAY 2022